优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN20186 | PRT-060318 | 1194961-19-7 | PRT-060318 is an inhibitor of Syk with IC50 of 4 nM. It is used to treat heparin-induced thrombocytopenia (HIT). |
| CSN20269 | Elimusertib | 1876467-74-1 | BAY-1895344 is a potent and selective ATR inhibitor with IC50 of 7 nM. |
| CSN20212 | N-(1',2-Dihydroxy-[1,2'-binaphthalen]-4'-yl)-4-methoxybenzenesulfonamide | 432001-19-9 | C188-9 is a STAT3 inhibitor and has no effects on non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in mice. |
| CSN156393 | N-(1',2-Dihydroxy-[1,2'-binaphthalen]-4'-yl)-4-methoxybenzenesulfonamide | 432001-19-9 | |
| CSN20262 | Lanreotide | 108736-35-2 | Lanreotide, a synthetic cyclic octapeptide, is the analogue of somatostatin that can inhibit somatostatin receptor 2 (SSTR-2). |
| CSN20188 | R428 R-Enantiomer | 1037624-76-2 | R428 R-enantiomer is an R isomer of R428, a potent and selective small-molecule inhibitor (IC50=14 nM), blocks the activities of Axl. |
| CSN20306 | SAR-020106 | 1184843-57-9 | SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC (50) of 13.3 nmol/L on the isolated human enzyme. This compound abrogates an etoposide-induced G (2) arrest with an IC (50) of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion. |
| CSN20259 | CU-CPT17e | 2109805-75-4 | CU-CPT17e is a multi-Toll-like receptor (TLR3/8/9) agonist with proinflammatory and anticancer activities. |
| CSN20272 | 27-Hydroxycholesterol | 20380-11-4 | 27-Hydroxycholesterol is an endogenous oxysterol with multiple biological functions, including activity as a selective estrogen receptor modulator (SERM) (a mixed, tissue-specific agonist-antagonist of the estrogen receptor (ER)) and as an agonist of the liver X receptor (LXR). It is a metabolite of cholesterol that is produced by the enzyme CYP27A1. |
| CSN20231 | ROC-325 | 1859141-26-6 | ROC-325 is an inhibitor of autophagy with promising anti-leukemic activity, which diminishes AML cell viability with the IC50 range of 0.7-2.2 μM. |
| CSN20317 | Linrodostat | 1923833-60-6 | BMS-986205 is a specific and irreversible inhibitor of IDO1 with IC50 value of 1.7 nM. |
| CSN20228 | PF-9366 | 72882-78-1 | PF-9366 is an allosteric inhibitor of Mat2A that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B, targeting S-adenosylmethionine biosynthesis, with IC50 of 420 nM and Kd of 170 nM, respectively. |
| CSN20311 | Irosustat | 288628-05-7 | Irosustat is a potent, irreversible inhibitor of steroid sulfatase. |
| CSN20256 | IDF-11774 | 1429054-28-3 | IDF-11774 is a hypoxia-inducible factor (HIF)-1α inhibitor which regulates cancer metabolism, thereby suppressing tumor growth. |
| CSN20225 | MHY553 | 6265-56-1 | MHY553, a PPARα agonist, alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. |
| CSN20247 | REV 5901 | 101910-24-1 | Rev-5901 is an antagonist of cysteinyl-leukotriene receptors with a Ki value of 0.7 µM for guinea pig lung membranes. It is also an inhibitor of rat neutrophil 5-LO with an IC50 value of 0.12 µM. |
| CSN20291 | Ormeloxifene | 31477-60-8 | Ormeloxifene, an estrogen receptor regulator, suppresses prostate tumor growth and metastatic phenotypes via inhibition of oncogenic β-catenin signaling and EMT progression |
| CSN20196 | MST-312 | 368449-04-1 | MST-312, also called Telomerase inhibitor IX, is a synthetic compound that acts as a reversible TERT (telomerase) inhibitor, and is described to be more potent than epigallocatechin gallate. |
| CSN20281 | SL 0101-1 | 77307-50-7 | SL0101 is a selective inhibitor of ribosomal S6 kinase (RSK) (IC50 = 89 nM for RSK2) which does not inhibit upstream kinases such as MEK, Raf and PKC. SL0101 Inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line. |
| CSN20261 | Lanreotide xacetate | 127984-74-1 | Lanreotide acetate is an a synthetic cyclic octapeptide analogue of somatostatin exhibiting a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. |
| CSN20187 | GDC-0326 | 1282514-88-8 | GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor). GDC-0326 achieves a very high level of selectivity over other kinases. |
| CSN20226 | CM-272 | 1846570-31-7 | CM-272 is a potent, selective and reversible dual small molecule against G9a and DNMTs activity. |
| CSN20223 | 2-Amino-7-(dimethylamino)-4-(4-(dimethylamino)naphthalen-1-yl)-4H-chromene-3-carbonitrile | 1384170-58-4 | SP-6-27, a microtubule inhibitor, inhibits angiogenesis and induces apoptosis in ovarian cancer cells. |
| CSN20206 | Bj-1301 | 1287234-48-3 | BJ-1301 is a promising candidate for the management of tumor agiongenesis and growth via inhibition of RTK and NADPH oxidase activities. |
| CSN20214 | SN32976 | 1246202-11-8 | SN32976 is a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors. |
| CSN20232 | Clk Inhibitor C21b | 2101206-26-0 | Clk inhibitor C21b, a potent inhibitor of Clk1 and -4 (IC50 = 7 and 2.3 nM, respectively), exhibits an unprecedented selectivity over Dyrk1A. It triggered the depletion of EGFR, HDAC1, and p70S6 kinase from the cancer cells, with potencies in line with the measured GI50 values. |
| CSN20194 | α-Cembrenediol | 57605-80-8 | VEGFR inhibitor TC1 acts in angiogenesis inhibitory in multiple breast cancer cell lines by significantly reducing the activated VEGFR2 levels. |
| CSN20215 | Wx-132-18b | 1415262-07-5 | WX-132-18B is a microtubule inhibitor, exhibits promising anti-tumor effects. |
| CSN20234 | FTI-277 Trifluoroacetate | 1217447-06-7 | FTI-277 trifluoroacetate is an inhibitor of farnesyl transferase (FTase) and a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. |
| CSN20240 | Elocalcitol | 199798-84-0 | Elocalcitol is a vitamin D3 analog having agonistic activities at vitamin D receptor (VDR). |
| CSN20242 | A-893 | 1868232-32-9 | A-893 is a potent and selective SMYD2 inhibitor (IC50: 2.8 nM). |
| CSN20245 | HDAC Inhibitor C4j | 2098896-13-8 | HDAC inhibitor C4j is a potent HDAC inhibitor in the cellular HDAC assay, revealed remarkable chemosensitizing properties and enhanced the cisplatin sensitivity of the cisplatin-resistant head-neck cancer cell line Cal27CisR by almost sevenfold. Furthermore, 4j almost completely reversed the cisplatin resistance in Cal27CisR. |
| CSN20282 | Su-10994 | 748153-84-6 | SU-10994 is a VEGFR inhibitor with potential anticancer activity. |
| CSN20246 | LPE-1 | 1637373-70-6 | LPE-1 is a histone lysine specific demethylase 1 (LSD1) (IC50=0.336±0.003μM) inhibitor selectively suppressed the viability of esophageal cancer cell line (EC-109) bearing overexpressed LSD1. It can significantly suppressed proliferation, induced apoptosis, arrested cell cycle of EC109 cells at G2/M phase, and caused changes of the associated protein markers correspondingly. |
| CSN20283 | MM-589 | 2097887-20-0 | MM-589 is a potent inhibitor of the WD repeat domain 5 protein (WDR5)–mixed lineage leukemia (MLL) interaction, and may yield a therapy for acute leukemia. |
| CSN20248 | CarbORev-5901 | 104325-75-9 | CarbORev-5901 is a carborane-based inhibitor of the 5-lipoxygenase pathway. |
| CSN20276 | CLK-IN-T3 | 2109805-56-1 | Clk inhibitor T3 is a highly selective, stable CLK inhibitor with high specificity to CLK1-3 protein isoforms. |
| CSN20309 | LCL521 | 1226851-11-1 | LCL521, an inhibitor of acid ceramidase, shows anticancer actions of lysosomally targeted. |
| CSN20284 | MM-589 TFA | 2253167-09-6 | MM-589 trifluoroacetate is a potent inhibitor of the WD repeat domain 5 protein (WDR5)–mixed lineage leukemia (MLL) interaction, and may yield a therapy for acute leukemia. |
| CSN20298 | MU380 | 2109805-78-7 | MU380 is a potent selective inhibitor of CHK1 kinase possessing unusual N-trifluoromethylpyrazole pharmacophore resistant to metabolic N-dealkylation |
| CSN20310 | LCL521 2HCl | 1226759-47-2 | LCL521 2HCl, an inhibitor of acid ceramidase, shows anticancer actions of lysosomally targeted. |
| CSN20264 | c-KIT/PDGFRα Inhibitor C31 | 2101755-69-3 | c-KIT/PDGFRα inhibitor C31 is a potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors GISTs). |
| CSN20323 | NF023 hexasodium | 104869-31-0 | NF023, a subtype-selective, competitive and reversible P2X1 receptor antagonist, displays IC50 values of 0.21, 28.9, > 50 and > 100 μM for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively. |
| CSN20325 | NAMPT Inhibitor C52 | 2109805-79-8 | NAMPT inhibitor C52 is a non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent antitumor activity when dosed orally in mouse xenograft models. |
| CSN20302 | PD-1-PDL1 Inhibitor C1a Hydrochloride | 2108101-94-4 | PD-1-PD-L1 inhibitor C1a is a potential inhibitor of PD-1/PD-L1 interaction which exhibits the structures capped on one side of the channel of PD-L1 homodimer. |
| CSN20315 | Smo Inhibitor C24 | 1567963-99-8 | Smo inhibitor C24 is a tetrahydropyrido[4,3-d]pyrimidine derivative that represent a set of Smo inhibitors that could potentially be utilized to treat medulloblastoma and other Hh pathway related malignancies. |
| CSN20326 | A-1293201 | 1375557-33-7 | A-1293201 is a non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent antitumor activity when dosed orally in mouse xenograft models. |
| CSN20303 | PD-1-PDL1 Inhibitor C2a Hydrochloride | N/A | PD-1-PD-L1 inhibitor C2a is a potential inhibitor of PD-1/PD-L1 interaction by inducing an enlarged interaction interface that results in the open 'face-back' tunnel through the PD-L1 dimer. |
